Table 4.

Follow-up information at 6 months

	Total N (%)	Tele-monitoring N (%)	Hospital Monitoring N (%)	P-value
Number of transmissions from consultation room
0	0 (0.0)	0 (0.0)	0 (0.0)	0.26
1	41 (83.7)	21 (84.0)	20 (83.3)
2	6 (12.2)	2 (8.0)	4 (16.7)
3	2 (4.1)	2 (8.0)	0 (0.0)
Transmissions from patients home
0	29 (59.2)	5 (20.0)	24 (100)	<  0.001
3–5	15 (30.6)	15 (60.0)	0 (0.0)
6–8	5 (10.2)	5 (20.0)	0 (0.0)
Extra transmissions from patients home
0	45 (91.8)	21 (84.0)	24 (100)	0.12
1	1 (2.0)	1 (4.0)	0 (0.0)
3	3 (6.2)	3 (12.0)	0 (0.0)
Cardiovascular adverse events
None	46 (93.9)	23 (92.0)	23 (95.8)	0.40
PCI	1 (2.0)	1 (4.0)	0 (0.0)
Angina	1 (2.0)	0 (0.0)	1 (4.2)
Lead dislodgement ×2	1 (2.0)	1 (2.0)	0 (0.0)
Changes of medication
0	33 (67.3)	17 (68.0)	16 (66.7)	0.11
1	7 (14.3)	5 (20.0)	2 (8.3)
2	3 (6.1)	1 (4.0)	2 (8.3)
3	4 (8.2)	0 (0.0)	4 (16.7)
4	2 (4.1)	2 (8.0)	0 (0.0)
Changes of pacemakers reprogramming
0	34 (69.4)	16 (64.0)	18 (75.0)	0.34
1	13 (26.5)	7 (28.0)	6 (25.0)
2	2 (4.1)	2 (8.0)	0 (0.0)
Hospitalizations days after implant
0	30 (61.2)	14 (56.0)	16 (66.7)	0.55
1	14 (28.6)	7 (28.0)	7 (29.2)
2	4 (8.2)	3 (12.0)	1 (4.2)
5	1 (2.0)	1 (2.0)	0 (0.0)
Days hospitalizated
0	30 (61.2)	14 (56.0)	16 (66.7)	0.54
1–5	12 (24.5)	6 (24.0)	6 (25.1)
6–10	4 (8.1)	2 (8.0)	2 (8.4)
+ 10	3 (6.0)	3 (12.0)	0 (0.0)
Reasons for hospitalization
None	30 (61.2)	14 (56.0)	16 (66.7)	0.37
Others	6 (12.3)	3 (12.0)	3 (12.5)
Cancer	1 (2.0)	1 (4.0)	0 (0.0)
Coronary problems	9 (18.4)	4 (16.0)	5 (20.8)
PM disfuction	3 (6.1)	3 (12.0)	0 (0.0)

TM tele-monitoring group, HM hospital monitoring group, N (month 6) = 49 (TM group: 25; HM group: 24). Items values are expressed as N (%). PCI percutaneous coronary intervention, PM pacemakers